{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:39:01Z","timestamp":1790959141864,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100016957","name":"Mirati Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s11523-022-00931-9","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T02:57:31Z","timestamp":1669949851000},"page":"105-118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors"],"prefix":"10.1007","volume":"18","clinical-trial-number":[{"clinical-trial-number":"nct00697632","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Christian","family":"Kollmannsberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Hurwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyudmila","family":"Bazhenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keunchil","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Reckamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirak","family":"Der-Torossian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demiana","family":"Faltaos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Potvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Tassell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey I.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"issue":"21","key":"931_CR1","doi-asserted-by":"publisher","first-page":"6661","DOI":"10.1158\/1078-0432.CCR-17-1192","volume":"23","author":"LD Engstrom","year":"2017","unstructured":"Engstrom LD, Aranda R, Lee M, Tovar EA, Essenburg CJ, Madaj Z, et al. Glesatinib exhibits antitumor activity in lung cancer models and patients harboring MET exon 14 mutations and overcomes mutation-mediated resistance to type I MET inhibitors in nonclinical models. Clin Cancer Res. 2017;23(21):6661\u201372. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1192.","journal-title":"Clin Cancer Res"},{"key":"931_CR2","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.2147\/OTT.S231257","volume":"13","author":"H Liang","year":"2020","unstructured":"Liang H, Wang M. MET oncogene in non-small cell lung cancer: Mechanism of MET dysregulation and agents targeting the HGF\/c-Met Axis. Onco Targets Ther. 2020;13:2491\u2013510. https:\/\/doi.org\/10.2147\/OTT.S231257.","journal-title":"Onco Targets Ther"},{"issue":"22","key":"931_CR3","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1002\/cncr.33159","volume":"126","author":"A Friedlaender","year":"2020","unstructured":"Friedlaender A, Drilon A, Banna GL, Peters S, Addeo A. The METeoric rise of MET in lung cancer. Cancer. 2020;126(22):4826\u201337. https:\/\/doi.org\/10.1002\/cncr.33159.","journal-title":"Cancer"},{"issue":"1","key":"931_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.21037\/atm.2016.12.67","volume":"5","author":"HM Jeon","year":"2017","unstructured":"Jeon HM, Lee J. MET: roles in epithelial\u2013mesenchymal transition and cancer stemness. Ann Transl Med. 2017;5(1):5. https:\/\/doi.org\/10.21037\/atm.2016.12.67.","journal-title":"Ann Transl Med."},{"issue":"6","key":"931_CR5","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41568-018-0002-y","volume":"18","author":"PM Comoglio","year":"2018","unstructured":"Comoglio PM, Trusolino L, Boccaccio C. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. Nat Rev Cancer. 2018;18(6):341\u201358. https:\/\/doi.org\/10.1038\/s41568-018-0002-y.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"931_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc3205","volume":"12","author":"E Gherardi","year":"2012","unstructured":"Gherardi E, Birchmeier W, Birchmeier C, Vande WG. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12(2):89\u2013103. https:\/\/doi.org\/10.1038\/nrc3205.","journal-title":"Nat Rev Cancer"},{"issue":"24","key":"931_CR7","doi-asserted-by":"publisher","first-page":"37370","DOI":"10.18632\/oncotarget.8276","volume":"7","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Du Z, Zhang M. Biomarker development in MET-targeted therapy. Oncotarget. 2016;7(24):37370\u201389. https:\/\/doi.org\/10.18632\/oncotarget.8276.","journal-title":"Oncotarget"},{"issue":"5","key":"931_CR8","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/cncr.28454","volume":"120","author":"X An","year":"2014","unstructured":"An X, Wang F, Shao Q, Wang FH, Wang ZQ, Wang ZQ, et al. MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent\/metastatic gastric cancer after chemotherapy. Cancer. 2014;120(5):675\u201382. https:\/\/doi.org\/10.1002\/cncr.28454.","journal-title":"Cancer"},{"issue":"11","key":"931_CR9","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1200\/JCO.18.00177","volume":"37","author":"GGY Lai","year":"2019","unstructured":"Lai GGY, Lim TH, Lim J, Liew PJR, Kwang XL, Nahar R, et al. Clonal MET amplification as a determinant of tyrosine kinase inhibitor resistance in epidermal growth factor receptor-mutant non-small-cell lung cancer. J Clin Oncol. 2019;37(11):876\u201384. https:\/\/doi.org\/10.1200\/JCO.18.00177.","journal-title":"J Clin Oncol"},{"issue":"2","key":"931_CR10","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/hep.26402","volume":"58","author":"K Wang","year":"2013","unstructured":"Wang K, Lim HY, Shi S, Lee J, Deng S, Xie T, et al. Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma. Hepatology. 2013;58(2):706\u201317. https:\/\/doi.org\/10.1002\/hep.26402.","journal-title":"Hepatology"},{"issue":"34","key":"931_CR11","doi-asserted-by":"publisher","first-page":"54627","DOI":"10.18632\/oncotarget.10559","volume":"7","author":"K Raghav","year":"2016","unstructured":"Raghav K, Morris V, Tang C, Morelli P, Amin HM, Chen K, et al. MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. 2016;7(34):54627\u201331. https:\/\/doi.org\/10.18632\/oncotarget.10559.","journal-title":"Oncotarget"},{"issue":"16","key":"931_CR12","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1158\/1078-0432.CCR-16-0951","volume":"22","author":"S Hartmann","year":"2016","unstructured":"Hartmann S, Bhola NE, Grandis JR. HGF\/Met signaling in head and neck cancer: impact on the tumor microenvironment. Clin Cancer Res. 2016;22(16):4005\u201313. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0951.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"931_CR13","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","volume":"5","author":"GM Frampton","year":"2015","unstructured":"Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015;5(8):850\u20139. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0285.","journal-title":"Cancer Discov"},{"issue":"9","key":"931_CR14","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.jtho.2016.06.004","volume":"11","author":"AB Schrock","year":"2016","unstructured":"Schrock AB, Frampton GM, Suh J, Chalmers ZR, Rosenzweig M, Erlich RL, et al. Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations. J Thorac Oncol. 2016;11(9):1493\u2013502. https:\/\/doi.org\/10.1016\/j.jtho.2016.06.004.","journal-title":"J Thorac Oncol"},{"key":"931_CR15","doi-asserted-by":"crossref","unstructured":"Rehman S, Dy GK. MET inhibition in non-small cell lung cancer. EMJ Respir. 2018;6(1):100\u201311. Available at: https:\/\/www.emjreviews.com\/oncology\/article\/met-inhibition-in-non-small-cell-lung-cancer\/.","DOI":"10.33590\/emj\/10314675"},{"issue":"12","key":"931_CR16","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1158\/1078-0432.CCR-16-0229","volume":"22","author":"A Drilon","year":"2016","unstructured":"Drilon A. MET exon 14 alterations in lung cancer: exon skipping extends half-life. Clin Cancer Res. 2016;22(12):2832\u20134. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0229.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"931_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107677","volume":"9","author":"A Dimou","year":"2014","unstructured":"Dimou A, Non L, Chae YK, Tester WJ, Syrigos KN. MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. PLoS ONE. 2014;9(9): e107677. https:\/\/doi.org\/10.1371\/journal.pone.0107677.","journal-title":"PLoS ONE"},{"issue":"12","key":"931_CR18","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-2061","volume":"22","author":"JH Tong","year":"2016","unstructured":"Tong JH, Yeung SF, Chan AW, Chung LY, Chau SL, Lung RW, et al. MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. Clin Cancer Res. 2016;22(12):3048\u201356. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2061.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"931_CR19","doi-asserted-by":"publisher","first-page":"10370","DOI":"10.1038\/s41598-018-28672-8","volume":"8","author":"V Vsiansky","year":"2018","unstructured":"Vsiansky V, Gumulec J, Raudenska M, Masarik M. Prognostic role of c-Met in head and neck squamous cell cancer tissues: a meta-analysis. Sci Rep. 2018;8(1):10370. https:\/\/doi.org\/10.1038\/s41598-018-28672-8.","journal-title":"Sci Rep"},{"issue":"1","key":"931_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084502","volume":"9","author":"Z Peng","year":"2014","unstructured":"Peng Z, Zhu Y, Wang Q, Gao J, Li Y, Li Y, et al. Prognostic significance of MET amplification and expression in gastric cancer: a systematic review with meta-analysis. PLoS ONE. 2014;9(1): e84502. https:\/\/doi.org\/10.1371\/journal.pone.0084502.","journal-title":"PLoS ONE"},{"issue":"10","key":"931_CR21","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMoa2004407","volume":"383","author":"PK Paik","year":"2020","unstructured":"Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med. 2020;383(10):931\u201343. https:\/\/doi.org\/10.1056\/NEJMoa2004407.","journal-title":"N Engl J Med"},{"issue":"10","key":"931_CR22","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa2002787","volume":"383","author":"J Wolf","year":"2020","unstructured":"Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, et al. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020;383(10):944\u201357. https:\/\/doi.org\/10.1056\/NEJMoa2002787.","journal-title":"N Engl J Med"},{"issue":"10","key":"931_CR23","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/S2213-2600(21)00084-9","volume":"9","author":"S Lu","year":"2021","unstructured":"Lu S, Fang J, Li X, Cao L, Zhou J, Guo Q, et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. Lancet Respir Med. 2021;9(10):1154\u201364. https:\/\/doi.org\/10.1016\/S2213-2600(21)00084-9.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"931_CR24","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/bjc.2016.428","volume":"116","author":"CM Gay","year":"2017","unstructured":"Gay CM, Balaji K, Byers LA. Giving AXL the axe: targeting AXL in human malignancy. Br J Cancer. 2017;116(4):415\u201323. https:\/\/doi.org\/10.1038\/bjc.2016.428.","journal-title":"Br J Cancer"},{"issue":"12","key":"931_CR25","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-17-0189","volume":"23","author":"TA Aguilera","year":"2017","unstructured":"Aguilera TA, Giaccia AJ. Molecular pathways: oncologic pathways and their role in T-cell exclusion and immune evasion: a new role for the AXL receptor tyrosine kinase. Clin Cancer Res. 2017;23(12):2928\u201333. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0189.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"931_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227187","volume":"15","author":"K Flem-Karlsen","year":"2020","unstructured":"Flem-Karlsen K, Nyakas M, Farstad IN, McFadden E, Wernhoff P, Jacobsen KD, et al. Soluble AXL as a marker of disease progression and survival in melanoma. PLoS ONE. 2020;15(1): e0227187. https:\/\/doi.org\/10.1371\/journal.pone.0227187.","journal-title":"PLoS ONE"},{"issue":"6","key":"931_CR27","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.clbc.2016.06.015","volume":"16","author":"K Tanaka","year":"2016","unstructured":"Tanaka K, Tokunaga E, Inoue Y, Yamashita N, Saeki H, Okano S, et al. Impact of expression of vimentin and Axl in breast cancer. Clin Breast Cancer. 2016;16(6):520\u20136. https:\/\/doi.org\/10.1016\/j.clbc.2016.06.015.","journal-title":"Clin Breast Cancer"},{"issue":"Suppl 3","key":"931_CR28","doi-asserted-by":"publisher","first-page":"S467","DOI":"10.1245\/s10434-012-2795-3","volume":"20","author":"M Ishikawa","year":"2013","unstructured":"Ishikawa M, Sonobe M, Nakayama E, Kobayashi M, Kikuchi R, Kitamura J, et al. Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients. Ann Surg Oncol. 2013;20(Suppl 3):S467\u201376. https:\/\/doi.org\/10.1245\/s10434-012-2795-3.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"931_CR29","first-page":"4155","volume":"36","author":"L Lozneanu","year":"2016","unstructured":"Lozneanu L, Pinciroli P, Ciobanu DA, Carcangiu ML, Canevari S, Tomassetti A, et al. Computational and immunohistochemical analyses highlight AXL as a potential prognostic marker for ovarian cancer patients. Anticancer Res. 2016;36(8):4155\u201363.","journal-title":"Anticancer Res"},{"issue":"24","key":"931_CR30","doi-asserted-by":"publisher","first-page":"36956","DOI":"10.18632\/oncotarget.9231","volume":"7","author":"MS Hsieh","year":"2016","unstructured":"Hsieh MS, Yang PW, Wong LF, Lee JM. The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma. Oncotarget. 2016;7(24):36956\u201370. https:\/\/doi.org\/10.18632\/oncotarget.9231.","journal-title":"Oncotarget"},{"issue":"3","key":"931_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2020.100134","volume":"2","author":"T Fujino","year":"2021","unstructured":"Fujino T. Acquired resistanced mechanism for MET tyrosine kinase inhibitor. JTO Clin Res Rep. 2021;2(3): 100134. https:\/\/doi.org\/10.1016\/j.jtocrr.2020.100134.","journal-title":"JTO Clin Res Rep"},{"issue":"10","key":"931_CR32","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.jtho.2019.06.023","volume":"14","author":"T Fujino","year":"2019","unstructured":"Fujino T, Kobayashi Y, Suda K, Koga T, Nishino M, Ohara S, et al. Sensitivity and resistance of MET exon 14 mutations in lung cancer to eight MET tyrosine kinase inhibitors in vitro. J Thorac Oncol. 2019;14(10):1753\u201365. https:\/\/doi.org\/10.1016\/j.jtho.2019.06.023.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"931_CR33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205\u201316. https:\/\/doi.org\/10.1093\/jnci\/92.3.205.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"931_CR34","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11523-022-00875-0","volume":"17","author":"A Patnaik","year":"2022","unstructured":"Patnaik A, Gadgeel S, Papadopoulos KP, Rasco DW, Haas NB, Der-Torossian H, et al. Phase I Study of glesatinib (MGCD265) in combination with erlotinib or docetaxel in patients with advanced solid tumors. Target Oncol. 2022;17(2):125\u201338. https:\/\/doi.org\/10.1007\/s11523-022-00875-0.","journal-title":"Target Oncol"},{"key":"931_CR35","doi-asserted-by":"publisher","first-page":"1000560","DOI":"10.4172\/2153-2435.1000560","volume":"8","author":"K Brake","year":"2017","unstructured":"Brake K, Gumireddy A, Tiwari A, Chauhan H, Kumari D. In vivo studies for drug development via oral delivery: challenges, animal models and techniques. Pharmaceutica Analytica Acta. 2017;8:1000560. https:\/\/doi.org\/10.4172\/2153-2435.1000560.","journal-title":"Pharmaceutica Analytica Acta."},{"issue":"10","key":"931_CR36","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/j.ajpath.2018.06.009","volume":"188","author":"A Tsagianni","year":"2018","unstructured":"Tsagianni A, Mars WM, Bhushan B, Bowen WC, Orr A, Stoops J, et al. Combined systemic disruption of MET and epidermal growth factor receptor signaling causes liver failure in normal mice. Am J Pathol. 2018;188(10):2223\u201335. https:\/\/doi.org\/10.1016\/j.ajpath.2018.06.009.","journal-title":"Am J Pathol"},{"issue":"1","key":"931_CR37","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.2217\/fon-2019-0653","volume":"16","author":"JW Clark","year":"2020","unstructured":"Clark JW, Camidge DR, Kwak EL, Maki RG, Shapiro GI, Chen I, et al. Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. Future Oncol. 2020;16(1):4289\u2013301. https:\/\/doi.org\/10.2217\/fon-2019-0653.","journal-title":"Future Oncol"},{"issue":"3","key":"931_CR38","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1007\/s10637-012-9881-z","volume":"31","author":"GI Shapiro","year":"2013","unstructured":"Shapiro GI, McCallum S, Adams LM, Sherman L, Weller S, Swann S, et al. A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. Invest New Drugs. 2013;31(3):742\u201350. https:\/\/doi.org\/10.1007\/s10637-012-9881-z.","journal-title":"Invest New Drugs"},{"issue":"1","key":"931_CR39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13073-019-0703-1","volume":"12","author":"ER Malone","year":"2020","unstructured":"Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med. 2020;12(1):8. https:\/\/doi.org\/10.1186\/s13073-019-0703-1.","journal-title":"Genome Med."},{"issue":"19","key":"931_CR40","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.87062","volume":"1","author":"LM Sholl","year":"2016","unstructured":"Sholl LM, Do K, Shivdasani P, Cerami E, Dubuc AM, Kuo FC, et al. Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016;1(19): e87062. https:\/\/doi.org\/10.1172\/jci.insight.87062.","journal-title":"JCI Insight."}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-022-00931-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-022-00931-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-022-00931-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T01:33:25Z","timestamp":1676597605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-022-00931-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["931"],"URL":"https:\/\/doi.org\/10.1007\/s11523-022-00931-9","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,2]]},"assertion":[{"value":"31 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study (NCT00697632) was supported by Mirati Therapeutics Inc. Funding for a professional medical writer with access to the data was provided by Mirati Therapeutics Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Herbert Hurwitz, Christian Kollmannsberger, Keunchil Park, and Sunil Sharma have no potential conflicts of interest to declare. Lyudmila Bazhenova reports consulting fees\/honoraria from Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sanko, Genentech, Janssen Pharmaceuticals, Merck, Mirati Therapeutics, Neuvogen, Novartis, ORIC Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, Takeda, and Turning Point Therapeutics (outside of the described work), and stock ownership in Epic Sciences. Byoung Chul Cho reports consulting fees\/honoraria from AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, MedPacto, Novartis, Ono Pharmaceuticals, Pfizer, Roche, and Yuhan; grants from AbbVie, AstraZeneca, Bayer, Blueprint Medicines, Champions Oncology, Dizal Pharma, Dong-A ST, Eli Lilly, GIInovation, Interpark Bio, Janssen Pharmaceuticals, MedPacto, MOGAM Institute, MSD, Novartis, Ono Pharmaceuticals, and Yuhan; royalties from Champions Oncology (all outside of the described work); and stock ownership for BridgeBio Therapeutics, Cyrus Therapeutics, Gencurix, Interpark Bio Convergence, KANAPH Therapeutics, and TheraCan Vac. David Hong reports consulting fees\/honoraria from Abbvie, Adaptimmune Therapeutics, Alkermes, Alpha Insights, Amgen, Aucta Pharmaceuticals, AUM Biosciences, Axiom, Baxter, Bayer, Boxer Capital, BridgeBio, COR2ED, COG, Cowen, Deciphera Pharmaceuticals, Ecor1, Gennao Bio, Genentech, Gilead, GLG, Group H, Guidepoint, HCW Precision, ImmunoGen, Infinity Pharmaceuticals, Janssen, Liberum, MedaCorp, Medscape, Numab, Oncologia Brasil, Pfizer, Pharma Intelligence, POET Congress, Prime Oncology, RAIN, SeaGen, STCube, Takeda, Tavistock, Trieza Therapeutics, Turning Point Therapeutics, WebMD, YingLing Pharma, and Ziopharm Oncology; grants from AbbVie, Adaptimmune, Adlai-Nortye, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Deciphera Pharmaceuticals, Eisai, Endeavor Pharmaceuticals, Erasca, Fate Therapeutics, Genentech, Genmab, Ignyta, Infinity, Kite Pharma, Kyowa Kirin, Lilly, Loxo Oncology, Merck, Medimmune, Mirati Therapeutics, Mologen, Navier Medical, NCI-CTEP, Novartis, Numab Therapeutics, Pfizer, Pyramid Biosciences, Roche, SeaGen, Takeda, TCR<sup>2<\/sup> Therapeutics, Teckro, Turning Point Therapeutics, and VM Oncology (all outside of the described work); and ownership interests in Molecular Match, OncoResponse, and Telperian. Karen L. Reckamp reports research funding to her institution from Blueprint Medicines, Calithera, Daiichi Sanko, Elevation Oncology, Genentech, Janssen, and Mirati Therapeutics (outside of the described work); and consulting fees\/honoraria from Amgen, AstraZeneca, Blueprint Medicines, Daiichi Sanko, EMD Sereno, Genentech, GlaxoSmithKline, Janssen Pharmaceuticals, Lilly, Merck KGA, Mirati Therapeutics, Seattle Genetics, and Takeda (outside of the described work). Geoffrey I. Shapiro reports research funding from Bristol Myers Squibb, Eli Lilly, Merck KGaA\/EMD-Serono, Merck & Co., Sierra Oncology, and Tango Therapeutics; and consulting fees\/honoraria from Artios, Atrin, Bayer, Bicycle Therapeutics, Blueprint Medicines, Boehringer Ingelheim, Concarlo Holdings, Cybrexa Therapeutics, CytomX Therapeutics, Eli Lilly, Fusion Pharmaceuticals, ImmunoMet, Janssen, Kymera Therapeutics, Merck KGaA\/EMD-Serono, Pfizer, Syros, Xinthera, and Zentalis (outside of the described work). He also reports a patent (also issued to Cyclacel Pharmaceuticals) entitled \u201cDosage regimen for sapacitabine and seliciclib\u201d, and a pending patent (with Liam Cornell) entitled \u201cCompositions and Methods for Predicting Response and Resistance to CDK4\/6 Inhibition\u201d. Richard Chao, James Christensen, Hirak Der-Torissian, and Vanessa Tassell report employment and stock ownership for Mirati Therapeutics. Diane Potvin reports prior\u00a0employment for Mirati Therapeutics. Demiana Faltaos reports prior employment and stock ownership for Mirati Therapeutics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Study conception and design: JGC, RC, HDT, DF, VT. Investigation: CK, HH, LB, BCC, DH, KP, KLR, SS, GS. Data analysis: DP, DF. Data interpretation: All authors. Manuscript reviewing and editing: All authors. Manuscript original draft: No authors, see medical writing acknowledgment. All authors reviewed and approved the final draft of the manuscript for publication and agree to be accountable for all aspects of the work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"At Mirati Therapeutics, we are committed to patient care, advancing scientific understanding, and enabling the scientific community to learn from and build upon the research we have undertaken. To that end, we will honor legitimate requests for our clinical trial data from qualified researchers and investigators for conducting methodologically sound research. We will share clinical trial data, clinical study reports, study protocols, and statistical analysis plans from clinical trials for this study. Sharing is subject to the protection of patient privacy and respect for patient informed consent. In general, data will be made available for specific requests approximately 24 months after clinical trial completion from our in-scope interventional trials. For additional information on proposals with regard to data-sharing collaborations with Mirati, please email medinfo@mirati.com.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki, International Conference on Harmonisation Guidelines for Good Clinical Practice, and local regulatory requirements. The study protocol was approved by the Institutional Review Board at each participating study site.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patients provided written, informed consent","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors gave approval for the final version to be published.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}